Charles River Laboratories International, Inc. last reported quarterly results on Nov 4, 2026, for Q3 FY2026 (the quarter ended Sep 26, 2026): revenue of $982.7 million (-2.2% year over year) and diluted EPS of $6.86. It usually reports 17–40 days after a quarter ends. Based on that pattern, the next release is estimated for around Jan 12, 2027.
Results for Q4 FY2026, the quarter ending around Dec 26, 2026. Expected on a Tuesday. Based on last year's release for the same quarter on Jan 13, 2026. This is an estimate, not a date the company has announced.
Release dates are when the company filed its earnings announcement with the SEC (Form 8-K, Item 2.02); select a date to open the filing. It usually reports 17–40 days after a quarter ends. Figures are USD in millions, except EPS. The colored percent is the change from the same quarter a year earlier. Until a quarter's 10-Q or 10-K figures reach the SEC's data, they come from the earnings press release, and are shown only when its year-ago numbers match the filed ones. A dash means the figure could not be confirmed yet.
| Released | Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|---|
|
Nov 4, 2026
39 days after quarter end
|
Q3 FY2026
ended Sep 26, 2026
|
983
-2.2%
|
333
+512.0%
|
6.86
+523.6%
|
|
Aug 5, 2026
39 days after quarter end
|
Q2 FY2026
ended Jun 27, 2026
|
1,004
-2.7%
|
-1
-102.8%
|
-0.03
-102.8%
|
|
May 7, 2026
40 days after quarter end
|
Q1 FY2026
ended Mar 28, 2026
|
996
+1.2%
|
-15
-158.3%
|
-0.30
-160.0%
|
|
Jan 13, 2026
17 days after quarter end
|
Q4 FY2025
ended Dec 27, 2025
|
994
-0.8%
|
-277
-28.9%
|
-5.68
-35.4%
|
|
Nov 5, 2025
39 days after quarter end
|
Q3 FY2025
ended Sep 27, 2025
|
1,005
-0.5%
|
54
-21.9%
|
1.10
-17.3%
|
|
Aug 6, 2025
39 days after quarter end
|
Q2 FY2025
ended Jun 28, 2025
|
1,032
+0.6%
|
52
-44.4%
|
1.06
-39.1%
|
|
May 7, 2025
39 days after quarter end
|
Q1 FY2025
ended Mar 29, 2025
|
984
-2.7%
|
25
-65.1%
|
0.50
-61.5%
|
|
Feb 19, 2025
53 days after quarter end
|
Q4 FY2024
ended Dec 28, 2024
|
1,003
-1.1%
|
-214
-214.7%
|
-4.20
-215.2%
|
Company profile
- Industry
- Services-Commercial Physical & Biological Research (SIC 8731)
- Listed as
- CRL (NYSE)
- Fiscal year ends
- December 27
- Headquarters
- Wilmington, MA
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1100682
- Former names
- CHARLES RIVER LABORATORIES INTERNATIONAL INC (until May 30, 2019); CHARLES RIVER LABORATORIES HOLDINGS INC (until Jan 28, 2000)
Other Services-Commercial Physical & Biological Research companies
- Iqvia Holdings Inc. IQV
- Incyte Corp INCY
- Medpace Holdings, Inc. MEDP
- Icon PLC ICLR
- Absci Corp ABSI
- OmniAb, Inc. OABI
- NRC Health NRC
- Maxcyte, Inc. MXCT
All 17 Services-Commercial Physical & Biological Research companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.